PID No.
 : MED121763958
 Register On
 : 27/03/2023 8:08 AM

 SID No.
 : 123005103
 Collection On
 : 27/03/2023 8:46 AM

 Age / Sex
 : 55 Year(s) / Female
 Report On
 : 28/03/2023 9:26 PM

 Age / Sex
 : 55 Year(s) / Female
 Report On
 : 28/03/2023 9:26 PM

 Type
 : OP
 Printed On
 : 01/04/2023 12:24 PM

Ref. Dr : MediWheel



Investigation	Observed Value	<u>Unit</u>	<u>Biological</u> Reference Interval
BLOOD GROUPING AND Rh TYPING	'A' 'Positive'		. ISIO CITE MILE VI
(EDTA Blood/Agglutination)			
INTERPRETATION: Reconfirm the Blood grou	p and Typing before	e blood transfusion	
Complete Blood Count With - ESR			
Haemoglobin (EDTA Blood/Spectrophotometry)	11.1	g/dL	12.5 - 16.0
Packed Cell Volume(PCV)/Haematocrit (EDTA Blood/Derived from Impedance)	34.2	%	37 - 47
RBC Count (EDTA Blood/Impedance Variation)	4.33	mill/cu.mm	4.2 - 5.4
Mean Corpuscular Volume(MCV) (EDTA Blood/Derived from Impedance)	78.9	fL	78 - 100
Mean Corpuscular Haemoglobin(MCH) (EDTA Blood/Derived from Impedance)	25.7	pg	27 - 32
Mean Corpuscular Haemoglobin concentration(MCHC) (EDTA Blood/Derived from Impedance)	32.5	g/dL	32 - 36
RDW-CV (EDTA Blood/Derived from Impedance)	17.0	%	11.5 - 16.0
RDW-SD (EDTA Blood/Derived from Impedance)	46.95	fL	39 - 46
Total Leukocyte Count (TC) (EDTA Blood/Impedance Variation)	8600	cells/cu.mm	4000 - 11000
Neutrophils (EDTA Blood/Impedance Variation & Flow Cytometry)	66.6	%	40 - 75
T 1 .	26.5	er.	20 45



(EDTA Blood/Impedance Variation & Flow

Lymphocytes

Cytometry)



26.5



20 - 45

APPROVED BY

The results pertain to sample tested.

Page 1 of 9

: MediWheel

 PID No.
 : MED121763958
 Register On
 : 27/03/2023 8:08 AM

 SID No.
 : 123005103
 Collection On
 : 27/03/2023 8:46 AM

 Age / Sex
 : 55 Year(s) / Female
 Report On
 : 28/03/2023 9:26 PM

Printed On



Type : OP

Ref. Dr

Investigation	Observed Value	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Eosinophils (EDTA Blood/Impedance Variation & Flow Cytometry)	2.2	%	01 - 06
Monocytes (EDTA Blood/Impedance Variation & Flow Cytometry)	4.2	%	01 - 10
Basophils (EDTA Blood/Impedance Variation & Flow Cytometry)	0.5	%	00 - 02
INTERPRETATION: Tests done on Automated	Five Part cell count	er. All abnormal results a	re reviewed and confirmed microscopically.
Absolute Neutrophil count (EDTA Blood/Impedance Variation & Flow Cytometry)	5.73	10^3 / μl	1.5 - 6.6
Absolute Lymphocyte Count (EDTA Blood/Impedance Variation & Flow Cytometry)	2.28	10^3 / μl	1.5 - 3.5
Absolute Eosinophil Count (AEC) (EDTA Blood/Impedance Variation & Flow Cytometry)	0.19	10^3 / μl	0.04 - 0.44
Absolute Monocyte Count (EDTA Blood/Impedance Variation & Flow Cytometry)	0.36	10^3 / μl	< 1.0
Absolute Basophil count (EDTA Blood/Impedance Variation & Flow Cytometry)	0.04	10^3 / μl	< 0.2
Platelet Count (EDTA Blood/Impedance Variation)	362	10^3 / μ1	150 - 450
MPV (EDTA Blood/Derived from Impedance)	10.2	fL	8.0 - 13.3
PCT (EDTA Blood/Automated Blood cell Counter)	0.37	%	0.18 - 0.28
ESR (Erythrocyte Sedimentation Rate)	33	mm/hr	< 30

: 01/04/2023 12:24 PM



(Blood/Automated - Westergren method)





APPROVED BY

The results pertain to sample tested.

Page 2 of 9

 PID No.
 : MED121763958
 Register On
 : 27/03/2023 8:08 AM

 SID No.
 : 123005103
 Collection On
 : 27/03/2023 8:46 AM

Age / Sex: 55 Year(s) / Female **Report On**: 28/03/2023 9:26 PM

Printed On

Type : OP

Ref. Dr : MediWheel



Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	<u>Biological</u> Reference Interval
BUN / Creatinine Ratio	15.46		6.0 - 22.0
Glucose Fasting (FBS) (Plasma - F/GOD-PAP)	125.6	mg/dL	Normal: < 100 Pre Diabetic: 100 - 125 Diabetic: >= 126

: 01/04/2023 12:24 PM

INTERPRETATION: Factors such as type, quantity and time of food intake, Physical activity, Psychological stress, and drugs can influence blood glucose level.

Glucose, Fasting (Urine)	Negative		Negative
(Urine - F/GOD - POD)			
Glucose Postprandial (PPBS)	182.9	mg/dL	70 - 140

(Plasma - PP/GOD-PAP)

INTERPRETATION:

Factors such as type, quantity and time of food intake, Physical activity, Psychological stress, and drugs can influence blood glucose level. Fasting blood glucose level may be higher than Postprandial glucose, because of physiological surge in Postprandial Insulin resistance, Exercise or Stress, Dawn Phenomenon, Somogyi Phenomenon, Anti- diabetic medication during treatment for Diabetes.

Urine Glucose(PP-2 hours) (Urine - PP)	Positive(+)		Negative
Blood Urea Nitrogen (BUN) (Serum/Urease UV / derived)	13.3	mg/dL	7.0 - 21
Creatinine (Serum/Modified Laffe)	0.86	mg/dL	0.6 - 1.1

(Serum/Modified Jaffe)

INTERPRETATION: Elevated Creatinine values are encountered in increased muscle mass, severe dehydration, Pre-eclampsia, increased ingestion of cooked meat, consuming Protein/ Creatine supplements, Diabetic Ketoacidosis, prolonged fasting, renal dysfunction and drugs such as cefoxitin, cefazolin, ACE inhibitors, angiotensin II receptor antagonists, N-acetylcysteine, chemotherapeutic agent such as flucytosine etc.

Uric Acid	5.5	mg/dL	2.6 - 6.0

(Serum/Enzymatic)

Liver Function Test

Bilirubin(Total)	0.69	mg/dL	0.1 - 1.2
(Serum/DCA with ATCS)			









APPROVED BY

 PID No.
 : MED121763958
 Register On
 : 27/03/2023 8:08 AM

 SID No.
 : 123005103
 Collection On
 : 27/03/2023 8:46 AM

 Age / Sex
 : 55 Year(s) / Female
 Report On
 : 28/03/2023 9:26 PM

Printed On



Ref. Dr : MediWheel

: OP

Type

Investigation	Observed Value	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Bilirubin(Direct) (Serum/Diazotized Sulfanilic Acid)	0.17	mg/dL	0.0 - 0.3
Bilirubin(Indirect) (Serum/Derived)	0.52	mg/dL	0.1 - 1.0
SGOT/AST (Aspartate Aminotransferase) (Serum/Modified IFCC)	13.1	U/L	5 - 40
SGPT/ALT (Alanine Aminotransferase) (Serum/Modified IFCC)	18.5	U/L	5 - 41
GGT(Gamma Glutamyl Transpeptidase) (Serum/IFCC / Kinetic)	21.7	U/L	< 38
Alkaline Phosphatase (SAP) (Serum/Modified IFCC)	135.3	U/L	53 - 141
Total Protein (Serum/Biuret)	6.93	gm/dl	6.0 - 8.0
Albumin (Serum/Bromocresol green)	4.17	gm/dl	3.5 - 5.2
Globulin (Serum/Derived)	2.76	gm/dL	2.3 - 3.6
A : G RATIO (Serum/Derived)	1.51		1.1 - 2.2
<u>Lipid Profile</u>			
Cholesterol Total (Serum/CHOD-PAP with ATCS)	205.2	mg/dL	Optimal: < 200 Borderline: 200 - 239 High Risk: >= 240
Triglycerides (Serum/GPO-PAP with ATCS)	107.5	mg/dL	Optimal: < 150 Borderline: 150 - 199 High: 200 - 499 Very High: >= 500

: 01/04/2023 12:24 PM







APPROVED BY

The results pertain to sample tested.

Page 4 of 9

PID No. Register On : 27/03/2023 8:08 AM : MED121763958 : 123005103 Collection On : 27/03/2023 8:46 AM SID No.

Age / Sex : 55 Year(s) / Female Report On : 28/03/2023 9:26 PM

Type : OP **Printed On** : 01/04/2023 12:24 PM

Ref. Dr : MediWheel



<u>Investigation</u>	Observed Unit	<u>Biological</u>
	<u>Value</u>	Reference Interval

INTERPRETATION: The reference ranges are based on fasting condition. Triglyceride levels change drastically in response to food, increasing as much as 5 to 10 times the fasting levels, just a few hours after eating. Fasting triglyceride levels show considerable diurnal variation too. There is evidence recommending triglycerides estimation in non-fasting condition for evaluating the risk of heart disease and screening for metabolic syndrome, as non-fasting sample is more representative of the 'usual_circulating level of triglycerides during most part of the day.

HDL Cholesterol (Serum/Immunoinhibition)	49.2	mg/dL	Optimal(Negative Risk Factor): >= 60 Borderline: 50 - 59 High Risk: < 50
LDL Cholesterol (Serum/Calculated)	134.5	mg/dL	Optimal: < 100 Above Optimal: 100 - 129 Borderline: 130 - 159 High: 160 - 189 Very High: >= 190
VLDL Cholesterol (Serum/Calculated)	21.5	mg/dL	< 30
Non HDL Cholesterol (Serum/Calculated)	156.0	mg/dL	Optimal: < 130 Above Optimal: 130 - 159 Borderline High: 160 - 189 High: 190 - 219

Very High: ≥ 220

INTERPRETATION: 1. Non-HDL Cholesterol is now proven to be a better cardiovascular risk marker than LDL Cholesterol. 2.It is the sum of all potentially atherogenic proteins including LDL, IDL, VLDL and chylomicrons and it is the "new bad cholesterol" and is a co-primary target for cholesterol lowering therapy.

4.2 Total Cholesterol/HDL Cholesterol

Low Risk: 3.4 - 4.4 Ratio (Serum/Calculated)

Average Risk: 4.5 - 7.1 Moderate Risk: 7.2 - 11.0 High Risk: > 11.0

Optimal: < 3.3







APPROVED BY

Register On : 27/03/2023 8:08 AM : MED121763958 : 123005103 SID No. Collection On : 27/03/2023 8:46 AM

Age / Sex : 55 Year(s) / Female Report On : 28/03/2023 9:26 PM

Type : OP **Printed On** : 01/04/2023 12:24 PM

Ref. Dr : MediWheel

PID No.



Investigation	Observed <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Triglyceride/HDL Cholesterol Ratio (TG/HDL) (Serum/Calculated)	2.2		Optimal: < 2.5 Mild to moderate risk: 2.5 - 5.0 High Risk: > 5.0
LDL/HDL Cholesterol Ratio (Serum/Calculated)	2.7		Optimal: 0.5 - 3.0 Borderline: 3.1 - 6.0 High Risk: > 6.0
Glycosylated Haemoglobin (HbA1c)			
HbA1C (Whole Blood/HPLC)	7.1	%	Normal: 4.5 - 5.6 Prediabetes: 5.7 - 6.4 Diabetic: >= 6.5

INTERPRETATION: If Diabetes - Good control: 6.1 - 7.0 %, Fair control: 7.1 - 8.0 %, Poor control >= 8.1 %

Remark: please correlate clinically.

Estimated Average Glucose 157.07 mg/dL

(Whole Blood)

INTERPRETATION: Comments

HbA1c provides an index of Average Blood Glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.

Conditions that prolong RBC life span like Iron deficiency anemia, Vitamin B12 & Folate deficiency,

hypertriglyceridemia, hyperbilirubinemia, Drugs, Alcohol, Lead Poisoning, Asplenia can give falsely elevated HbA1C values. Conditions that shorten RBC survival like acute or chronic blood loss, hemolytic anemia, Hemoglobinopathies, Splenomegaly, Vitamin E ingestion, Pregnancy, End stage Renal disease can cause falsely low HbA1c.

THYROID PROFILE / TFT

0.94 0.4 - 1.81T3 (Triiodothyronine) - Total ng/ml

(Serum/Chemiluminescent Immunometric Assay

(CLIA))

INTERPRETATION:

Comment:

Total T3 variation can be seen in other condition like pregnancy, drugs, nephrosis etc. In such cases, Free T3 is recommended as it is Metabolically active.









APPROVED BY

The results pertain to sample tested.

Page 6 of 9

 PID No.
 : MED121763958
 Register On
 : 27/03/2023 8:08 AM

 SID No.
 : 123005103
 Collection On
 : 27/03/2023 8:46 AM

 Age / Sex
 : 55 Year(s) / Female
 Report On
 : 28/03/2023 9:26 PM

: OP Printed On : 01/04/2023 12:24 PM

Ref. Dr : MediWheel



Investigation	Observed Value	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
T4 (Tyroxine) - Total	8.18	μg/dl	4.2 - 12.0
(Serum/Chemiluminescent Immunometric Assay			
(CLIA))			

INTERPRETATION:

Comment:

Type

Total T4 variation can be seen in other condition like pregnancy, drugs, nephrosis etc. In such cases, Free T4 is recommended as it is Metabolically active.

TSH (Thyroid Stimulating Hormone) 2.10 µIU/mL 0.35 - 5.50

 $(Serum/{\it Chemiluminescent\ Immunometric\ Assay}$

(CLIA))

INTERPRETATION:

Reference range for cord blood - upto 20

1 st trimester: 0.1-2.5 2 nd trimester 0.2-3.0 3 rd trimester : 0.3-3.0

(Indian Thyroid Society Guidelines)

Comment:

1.TSH reference range during pregnancy depends on Iodine intake, TPO status, Serum HCG concentration, race, Ethnicity and BMI.

2.TSH Levels are subject to circadian variation, reaching peak levels between 2-4am and at a minimum between 6-10PM. The variation can be of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.

3. Values&lt 0.03 µIU/mL need to be clinically correlated due to presence of rare TSH variant in some individuals.

Urine Analysis - Routine

COLOUR (Urine)	Pale yellow	Yellow to Amber
APPEARANCE (Urine)	Clear	Clear
Protein (Urine/Protein error of indicator)	Negative	Negative
Glucose (Urine/GOD - POD)	Negative	Negative
Pus Cells (Urine/Automated Flow cytometry)	Occasional /hpf	NIL







APPROVED BY

The results pertain to sample tested.

Page 7 of 9

 PID No.
 : MED121763958
 Register On
 : 27/03/2023 8:08 AM

 SID No.
 : 123005103
 Collection On
 : 27/03/2023 8:46 AM

 Age / Sex
 : 55 Year(s) / Female
 Report On
 : 28/03/2023 9:26 PM

Printed On



Type : OP

Ref. Dr : MediWheel

Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Epithelial Cells (Urine/Automated ¬Flow cytometry)	2 - 3	/hpf	NIL
RBCs (Urine/Automated **Flow cytometry)	NIL	/hpf	NIL
Casts (Urine/Automated ¬Flow cytometry)	NIL	/hpf	NIL
Crystals (Urine/Automated ¬Flow cytometry)	NIL	/hpf	NIL
Others (Urine)	NIL		

: 01/04/2023 12:24 PM

INTERPRETATION: Note: Done with Automated Urine Analyser & Automated urine sedimentation analyser. All abnormal reports are reviewed and confirmed microscopically.

Stool Analysis - ROUTINE

Colour (Stool)	Yellow	Brown
Blood (Stool)	Absent	Absent
Mucus (Stool)	Absent	Absent
Reaction (Stool)	Acidic	Acidic
Consistency (Stool)	Semi Solid	Semi Solid
Ova (Stool)	NIL	NIL
Others (Stool)	NIL	NIL
Cysts (Stool)	NIL	NIL







APPROVED BY

The results pertain to sample tested.

Page 8 of 9

PID No. Register On : 27/03/2023 8:08 AM : MED121763958 : 123005103 SID No. Collection On : 27/03/2023 8:46 AM

Age / Sex : 55 Year(s) / Female Report On : 28/03/2023 9:26 PM

Type : OP

Ref. Dr : MediWheel

Printed On : 01/04/2023 12:24 PM



Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Trophozoites (Stool)	NIL		NIL
RBCs (Stool)	NIL	/hpf	Nil
Pus Cells (Stool)	1 - 2	/hpf	NIL
Macrophages (Stool)	NIL		NIL
Epithelial Cells (Stool)	NIL	/hpf	NIL







APPROVED BY

-- End of Report --

Name : Ms. KALAVATHY M Register On : 27/03/2023 8:08 AM

PID No. Collection On : 27/03/2023 8:46 AM : MED121763958

Report On : 28/03/2023 9:26 PM SID No. : 123005103

Printed On : 01/04/2023 12:24 PM Age / Sex : 55 Year(s) / Female

OP / IP Ref. Dr : MediWheel : OP

PAP Smear by LBC(Liquid based Cytology)

SPECIMEN NO : Cy 821/2023

MICROSCOPIC FINDINGS:

ADEQUACY: Satisfactory.

PREDOMINANT CELLS: Intermediate cells and a few

superficial cells.

BACKGROUND : Clean.

ORGANISMS: No specific organisms.

IMPRESSION:

Negative for intraepithelial lesion/ malignancy.





APPROVED BY

-- End of Report --

The results pertain to sample tested.

Page 1 of 1